Product Description
cyclophosphamide, doxorubicin, vincristine, prednisolone for a 14 day cycle (Sourced from: https://ascopubs.org/doi/10.1200/jco.2011.29.15_suppl.8000)
Mechanisms of Action: DNA Damager,Tubulin Inhibitor,GR Agonist
Novel Mechanism: Yes
Modality: N/A
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Aarhus University Hospital
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: T-Cell Peripheral Lymphoma
Phase 2: Diffuse Large B-Cell Lymphoma
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| ChiCTR-TRC-11001687 | N/A |
Recruiting |
Diffuse Large B-Cell Lymphoma |
2018-12-31 |
|||
| ChiCTR-TRC-08000243 | N/A |
Recruiting |
Lymphoma, B-Cell |
2017-12-31 |
|||
| LNH2007-3B | P2 |
Completed |
Diffuse Large B-Cell Lymphoma |
2013-10-01 |
2019-03-21 |
Treatments |
|
| ACT-1 | P3 |
Completed |
T-Cell Peripheral Lymphoma |
2016-12-31 |
2024-11-27 |
Primary Endpoints|Treatments |